FLT3 and acute myeloid leukemia: AML samples with high inflammatory response show immunosuppression, high expression of immune checkpoints and high infiltration of inflammatory cells, which are more suitable for immunotherapy; samples with low inflammatory response are more sensitive to the AML chemotherapy drugs cytarabine, doxorubicin, and the FLT3-targeting inhibitor midostaurin.